ENTRY
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads AVOID — it trades above our $6,793.18 fair value estimate, 11.50% revenue growth.
Read at
$7,450.00
28.25 P/E · 31.58 fwd
Our fair value
$6,793.18
9% premium
Analyst target (avg)
$9,800.00
+32% to current
Target low $8,000.00Analyst target rangeTarget high $13,500.00
▲ current $7,450.00 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard · AAOIFI
Used by most halal investing apps
✓ PASSES
Our stricter standard · asset-based
The one Titan applies
✗ DOES NOT PASS
What these two standards are, and how they differ →
-
Business activity
Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
-
Debt load
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
-
Interest-bearing cash
Cash held in interest-bearing accounts and securities is 22.4% of assets, under the one-third limit.
Pass
-
Receivables
Money owed to the company is 35.2% of assets, under the 49% limit.
Pass
-
Revenue purity
Only 0.0% of revenue comes from non-compliant sources — under the 5% line.
Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Why it gives us pause
At 31.6x forward earnings, the price already runs ahead of the business. It trades 9% above our $6,793.18 fair value, so you would be buying at a premium, not a discount.
The risks · The things to watch: its business and earnings are exposed to Japan and to currency swings; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
JOURNAL
The dated journal · newest first, never edited
2026-07-24
Markdown $7,450.00
+0.0% Entry 11
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $9973. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23
Markdown · changed $7,450.00
+0.0% Entry 10
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $9973. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-22
Distribution $7,450.00
+0.0% Entry 9
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $9973. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-21
Distribution $7,450.00
+0.0% Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $9973. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-20
Distribution $7,450.00
+0.0% Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $9973. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-19
Distribution $7,450.00
+0.0% Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $9973. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18
Distribution $7,450.00
+0.0% Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $9973. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-17
Distribution $7,450.00
+0.0% Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (15 analysts) rates it buy, with a mean price target of $9973. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-05
Distribution $7,450.00
Entry 3
5 July 2026 — ¥7,450 — DISTRIBUTION (state model: sideways, 17 days). Journal opened on a world-class business in autumn: 35% margins and a 103.8% three-year run, now 30% off the high with the forward multiple above the trailing one. Tensions on file: the quality itself, the street’s ¥9,800 against our consistent, harsh ¥3,128, empty insider file. Next review: the pause resolving through ¥7,560 or the estimates turning, whichever is first.
2026-07-03
Distribution $7,450.00
+0.0% Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.